Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation (2016 - 2026)

Rocket Pharmaceuticals' Accumulated Depreciation history spans 11 years, with the latest figure at $29.1 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation rose 37.03% to $29.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.1 million, a 37.03% increase, with the full-year FY2025 number at $29.1 million, up 37.03% from a year prior.
  • Accumulated Depreciation hit $29.1 million in Q4 2025 for Rocket Pharmaceuticals, up from $27.4 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for RCKT hit a ceiling of $29.1 million in Q4 2025 and a floor of $2.7 million in Q1 2021.
  • Historically, Accumulated Depreciation has averaged $13.7 million across 5 years, with a median of $12.0 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation: soared 200.35% in 2021 and later soared 37.03% in 2025.
  • Tracing RCKT's Accumulated Depreciation over 5 years: stood at $5.2 million in 2021, then surged by 74.1% to $9.1 million in 2022, then skyrocketed by 54.32% to $14.0 million in 2023, then surged by 51.46% to $21.3 million in 2024, then surged by 37.03% to $29.1 million in 2025.
  • Business Quant data shows Accumulated Depreciation for RCKT at $29.1 million in Q4 2025, $27.4 million in Q3 2025, and $25.7 million in Q2 2025.